Generic Drug Analysis & Statistics, October 2014 (p2)

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

31-60 of about 200 reports

Purchase Reports From Reputable Market Research Publishers

Fosaprepitant  - Patent, Extension and Data Exclusivity Expiry Snapshot (Nine countries)

Fosaprepitant - Patent, Extension and Data Exclusivity Expiry Snapshot (Nine countries)

  • $ 600
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Paliperidone  - Patent, Extension and Data Exclusivity Expiry Snapshot (Nine countries)

Paliperidone - Patent, Extension and Data Exclusivity Expiry Snapshot (Nine countries)

  • $ 600
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Ticagrelor  - Patent, Extension and Data Exclusivity Expiry Snapshot (Nine countries)

Ticagrelor - Patent, Extension and Data Exclusivity Expiry Snapshot (Nine countries)

  • $ 600
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Simeprevir  - Patent, Extension and Data Exclusivity Expiry Snapshot (Nine countries)

Simeprevir - Patent, Extension and Data Exclusivity Expiry Snapshot (Nine countries)

  • $ 600
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Elvitegravir  - Patent, Extension and Data Exclusivity Expiry Snapshot (Nine countries)

Elvitegravir - Patent, Extension and Data Exclusivity Expiry Snapshot (Nine countries)

  • $ 600
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Tolvaptan  - Patent, Extension and Data Exclusivity Expiry Snapshot (Nine countries)

Tolvaptan - Patent, Extension and Data Exclusivity Expiry Snapshot (Nine countries)

  • $ 600
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Aprepitant  - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

Aprepitant - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

  • $ 1 400
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Enzalutamide  - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

Enzalutamide - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

  • $ 1 400
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Fosaprepitant  - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

Fosaprepitant - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

  • $ 1 400
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Paliperidone  - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

Paliperidone - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

  • $ 1 400
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Ticagrelor  - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

Ticagrelor - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

  • $ 1 400
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Simeprevir  - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

Simeprevir - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

  • $ 1 400
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Elvitegravir  - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

Elvitegravir - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

  • $ 1 400
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
Tolvaptan  - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

Tolvaptan - Patent, Extension and Data Exclusivity Expiry Snapshot (Fifty countries)

  • $ 1 400
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, ...

  • Industries : Generic Drug
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely ...

  • Industries : Pharmaceutical, Hospitality, Hospitality, Drug and Medication, Tourism, Tourism
  • Countries : Europe, World, Asia
Biosimilars Business Review Q3 2014

Biosimilars Business Review Q3 2014

  • $ 1 114
  • Industry report
  • September 2014
  • by Espicom Business Intelligence

Industry Trend Analysis - Tests To FDA's Biosimilar Pathway Intensify Naming Debate Industry Trend Analysis - Sandoz Becomes First To Test FDA's Biosimilars Pathway Industry Brief - Liomont And Oncobiologics ...

  • Industries : Biopharmaceutical, Drug and Medication
  • Countries : Mexico, Japan, Europe, India
Glenmark Generics, Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Glenmark Generics, Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • September 2014
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Pharmaceutical
  • Countries : United States
Glenmark Generics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Glenmark Generics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • September 2014
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Pharmaceutical
  • Countries : United States
Glenmark Generics Inc., USA - Strategic SWOT Analysis Review

Glenmark Generics Inc., USA - Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • August 2014
  • by Global Data

Glenmark Generics Inc., USA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a ...

  • Industries : Generic Drug, Drug and Medication
  • Countries : United States
Analyzing the Global Generics Industry 2014

Analyzing the Global Generics Industry 2014

  • $ 1 750
  • Industry report
  • August 2014
  • by Aruvian's R'search

In recent times there has been a growing focus on the generic drugs industry worldwide. The patent expiry of leading drugs in recent years and also the upcoming patent expiries has put a focus on the global ...

  • Industries : Pharmaceutical, Generic Drug, Drug and Medication
  • Countries : Europe, World
Global Cancer Generics Market Outlook 2018

Global Cancer Generics Market Outlook 2018

  • $ 1 400
  • Industry report
  • August 2014
  • by RNCOS

With the advent of novel and innovative technologies, industries like healthcare and pharmaceutical are scaling newer heights. One such market is the oncology market. With global cancer incidences rising ...

  • Industries : Pathology, Pharmaceutical, Generic Drug, Drug and Medication
  • Countries : World
Biosimilars - Biosimilars on the cusp of a new era

Biosimilars - Biosimilars on the cusp of a new era

  • $ 2 995
  • Industry report
  • July 2014
  • by GBI Research

The biosimilars market is undergoing rapid change with developments such as the recent approvals of infliximab and trastuzumab heralding a new era. In order to keep up with the pace of change in the marketplace, ...

  • Industries : Biopharmaceutical, Generic Drug
Biosimilars - Biosimilars on the cusp of a new era, CBR Pharma Insights

Biosimilars - Biosimilars on the cusp of a new era, CBR Pharma Insights

  • $ 2 995
  • Industry report
  • July 2014
  • by CBR Pharma Insights

The biosimilars market is undergoing rapid change with developments such as the recent approvals of infliximab and trastuzumab heralding a new era. In order to keep up with the pace of change in the marketplace, ...

  • Industries : Generic Drug, Biopharmaceutical
  • Countries : Europe
Detailed I/E report of Fipronil export analysis

Detailed I/E report of Fipronil export analysis

  • $ 5 400
  • Industry report
  • July 2014
  • by CCM International Limited

Fipronil export analysis will help clients understandthe export situation of technical and formulations with exclusive research methods and offer not only the products’export volume, price, time, source ...

  • Industries : Generic Drug
Portugal Pharmaceuticals and Healthcare Report Q3 2014

Portugal Pharmaceuticals and Healthcare Report Q3 2014

  • $ 1 300
  • Industry report
  • July 2014
  • by Business Monitor International

Includes 3 FREE quarterly updates BMI View: Faster-than-expected economic growth last quarter has led us to revise our healthcare and pharmaceutical forecasts slightly upwards. As forecast previously, ...

  • Industries : Pharmaceutical, Drug and Medication, Healthcare
  • Countries : Portugal
PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market

PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market

  • $ 2 995
  • Industry report
  • June 2014
  • by Global Data

PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market Summary GlobalData’s report, "PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars ...

  • Industries : Generic Drug
  • Countries : Europe, India, China
Sandoz International GmbH - Strategy and SWOT Report

Sandoz International GmbH - Strategy and SWOT Report

  • $ 175
  • Company report
  • June 2014
  • by MarketLine

Sandoz International GmbH - SWOT Analysis company profile is the essential source for top-level company data and information. Sandoz International GmbH - SWOT Analysis examines the company’s key business ...

  • Industries : Pharmaceutical, Drug and Medication
  • Countries : United States
Fumarate De Formoterol-Drug Insights,2014

Fumarate De Formoterol-Drug Insights,2014

  • $ 1 000
  • Industry report
  • June 2014
  • by Delve Insight

DelveInsight’s pharmaceuticals report, “Fumarate De Formoterol - Drug Insights, 2014” provides Fumarate De Formoterol marketed details and API Manufacturers details across the globe along with the ...

  • Industries : Generic Drug
  • Countries : United States, Europe, World
Glenmark Generics Inc., USA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Glenmark Generics Inc., USA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • May 2014
  • by Global Data

Summary Glenmark Generics Inc., USA (Glenmark Generics) is a pharmaceutical company. It offers mainly generic pharmaceutical products. Some of the products of the company include adapalene, alclometasone ...

  • Industries : Generic Drug, Drug and Medication
  • Countries : United States
The Future of Biosimilars: mapping critical uncertainties and the impact of future events

The Future of Biosimilars: mapping critical uncertainties and the impact of future events

  • $ 2 194
  • Industry report
  • May 2014
  • by Firstword Pharma

The Future of Biosimilars: Mapping Critical Uncertainties and the Impact of Future Events offers timely insight into the critical biosimilar market issues, and how they could shape the continued evolution ...

  • Industries : Generic Drug, Biopharmaceutical
  • Countries : Europe, World

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.